A randomized multicenter trial of adjuvant IMF-001 after curative resection for esophageal cancer with NY-ESO-1 antigen (phase II study)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2016
At a glance
- Drugs IMF 001 (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 12 May 2015 Planned End Date changed from 1 Mar 2016 to 31 Oct 2017 as reported by University Hospital Medical Information Network - Japan.
- 17 May 2012 New trial record